When aberrantly expressed or activated, the Met receptor tyrosine kinase is involved in tumor invasiveness and metastasis. In this study, we have used the Xenopus embryonic system to define the role of various Met proximal-binding partners and downstream signaling pathways in regulating an induced morphogenetic event. We show that expression of an oncogenic derivative of the Met receptor (Tpr-Met) induces ectopic morphogenetic structures during Xenopus embryogenesis. Using variant forms of Tpr-Met that are engineered to recruit a specific signaling molecule of choice, we demonstrate that the sole recruitment of either the Grb2 or the Shc adaptor protein is sufficient to induce ectopic structures and anterior reduction, while the recruitment of PI-3Kinase (PI-3K) is necessary but not sufficient for this effect. In contrast, the recruitment of PLCc can initiate the induction, but fails to maintain or elongate supernumerary structures. Finally, evidence indicates that the Ras/Raf/MAPK pathway is necessary, but not sufficient to induce these structures. This study also emphasizes the importance of examining signaling molecules in the regulatory context that is provided by receptor/effector interactions when assessing a role in cell growth and differentiation.
Introduction
Activation of the Met tyrosine kinase by the TPR gene was originally described as a carcinogen-induced rearrangement in a human osteosarcoma cell line (Dean et al., 1987) . The Tpr-Met fusion protein contains constitutively elevated Met tyrosine kinase activity and constitutes an ideal model to study the transforming activity of the Met kinase. The Tpr portion of Tpr-Met encodes a leucine zipper motif, which mediates dimerization of Tpr-Met (Liu et al., 1992; Rodrigues and Park, 1993) . Protein dimerization mimics kinase activation of the full-length receptors following ligand binding and this may be a general mechanism for oncogenic activation of this family of receptor tyrosine kinases in human tumors (Rodrigues and Park, 1994) . In the case of Tpr-Met, the oncoprotein is a cytosolic tyrosine kinase that is constitutively active in the absence of ligand. The Met receptor is overexpressed and deregulated in a variety of human tumors, including gastric (Tsao et al., 1993) , thyroid (Di Renzo et al., 1992) , and colorectal (Liu et al., 1992) carcinomas, as well as sarcomas from various tissues (Rong et al., 1993; To and Tsao, 1998; Tsarfaty et al., 1999; Danilkovitch-Miagkova and Zbar, 2002; Maulik et al., 2002; Coltella et al., 2003; Zhang et al., 2003; Christensen et al., 2005; Gao and Vande Woude, 2005; Lengyel et al., 2005) . In addition, point mutations have been identified in the Met receptor in both hereditary and sporadic papillary renal carcinomas, implicating the Met receptor in human tumorigenesis (Rong et al., 1993; Jeffers et al., 1997; Schmidt et al., 1998; Gao and Vande Woude, 2005) . Activated oncogenes derived from receptor tyrosine kinases following chromosomal translocations have no mutations within their receptor-derived portions, suggesting that they are capable of activating the same signal transduction pathways as their full-length receptor counterparts, albeit in a constitutive fashion.
Tpr-Met and Met receptor signaling, as well as biological activity, are dependent on two phosphotyrosine residues outside of the catalytic domain (Tyrosines 482 and 489 in Tpr-Met, Tyrosines 1349 and 1356 in Met). Tyrosine 489 provides a direct binding site for the Grb2 and Shc adaptor proteins (Ponzetto et al., 1994; Fixman et al., 1995 Fixman et al., , 1996 . In addition, Tyrosine 482 and 489 are required for the recruitment of the docking protein Gab1 which couples the Met receptor with multiple downstream signaling proteins including PI-3K, PLCg, the tyrosine phosphatase SHP2 and the adaptor protein Crk (Weidner et al., 1996; Bardelli et al., 1997; Fixman et al., 1997; Nguyen et al., 1997; Maroun et al., 1999) . Moreover, Grb2 acts to indirectly recruit the c-Cbl ubiquitin ligase, and contributes to the recruitment of Gab1 (Bardelli et al., 1997; Fixman et al., 1997; Lock et al., 2000) , and the addition of a second Grb2-binding site enhances cell transformation (Bardelli et al., 1999) . One study generated Tpr-Met variants that specifically bind to the p85 subunit of PI-3K, PLCg, the Grb2 or Shc adaptor proteins and has analysed their ability to induce focus formation, anchorage-independent cell growth, dispersal of epithelial cells, and experimental metastasis. These studies demonstrate that the recruitment of the Grb2 or the Shc adaptor proteins to RTK-derived oncogenes is sufficient for morphological cell transformation and experimental metastasis (Saucier et al., 2002) .
The Xenopus system has proven to be a powerful tool for understanding the contribution of several protooncogenes and kinases to cell-cycle progression and developmental processes. During Xenopus development, expression of a dominant-negative form of the Met receptor resulted in impaired liver, pronephros, and gut development (Aoki et al., 1997) . Inappropriate expression of the Met ligand, Hepatocyte Growth Factor Scatter Factor (HGF/SF), in transgenic mice influences the development of two distinct migratory cell lineages that result in ectopic skeletal muscle formation and melanosis in the central nervous system, and patterned hyperpigmentation of the skin (Takayama et al., 1996 (Takayama et al., , 1997 . Blocking the HGF signaling pathway in Xenopus embryos by using truncated c-Met lacking the tyrosine kinase domain or HGF antisense morpholinos resulted in a marked decrease in the number of circulating blood cells (Koibuchi et al., 2004) .
To pursue the functional contributions of specific Met domains and motifs to signaling in an in vivo system, we examined the effect of overexpressing oncogenic mutant forms of Met during Xenopus development. Here, we show that a constitutively active oncogenic form of the Met tyrosine kinase induces ectopic protruding structures during Xenopus embryogenesis. Moreover, we have exploited this system to explore the functional effects of Tpr-Met-mediated phosphorylation and protein-protein interactions.
Results

Oncogenic Met induces ectopic morphogenetic structures
To explore the functional effect of Tpr-Met in vivo, we expressed wild-type oncogenic Tpr-Met in Xenopus embryos. mRNA (5 pg/embryo) encoding the Tpr-Met tyrosine kinase was injected into the animal pole of twocell stage embryos. At stage 20 (late neurula), a striking phenotype was observed in response to Tpr-Met expression, where the neural fold bifurcated in the anterior region of the embryo ( Figure 1b) . As expected, uninjected control embryos appeared normal (Figure 1a) . By the swimming tadpole stage, Tpr-Metexpressing embryos developed ectopic protrusions, evaginating from the anterior region. These structures often possessed fin mesenchyme, and in a significant subset of embryos (10%), eye formation was absent or dramatically reduced. (Figure 1b) . The vast majority of these tail-like structures emanated from the anterior dorsal region of the embryo, even though broad expression of Tpr-Met would be expected from injection into one blastomere of a two-cell stage embryo.
We next tested whether the expression of Tpr-Met in the neurectoderm alone was responsible for the ectopic structure. One animal-dorsal blastomere was injected with either b-galactosidase (b-gal) RNA alone, or with Tpr-Met RNA to restrict Tpr-Met expression to the neurectoderm region and b-gal staining served as a lineage tracer. Figure 2a shows that the b-gal RNAinjected embryos appear normal at stage 39, and embryos expressing Tpr-Met show that b-gal is restricted to the anterior region. Moreover, the eyes are dramatically reduced, and an ectopic protruding structure is formed from a significant portion of the Tpr-Metexpressing progeny cells (Figure 2b) .
It was possible that there may be differential activation and functional effects of this cytoplasmic form of oncogenic Met in vivo when compared to membrane-localized forms. To establish whether this was the case, we localized the constitutively activated Tpr-Met oncoprotein to the membrane using the c-Src myristylation signal (Kamikura et al., 2000) . Injection of the membrane-localized Tpr-Met RNA (SMS-Tpr-Met) at the same concentration as the cytoplasmic form (0.5 pg) resulted in the same protrusion phenotype in a similar percentage of embryos (Figure 2c, 75 and 70%, respectively) . 
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Tpr-Met induces tail and posterior neural markers As development proceeded to the tadpole stage, tail-like structures evolved from these protrusions and wholemount in situ hybridizations of embryos showed expression of the tail marker Xpo (Figure 3c, d ; Sato and Sargent, 1991) , and also stained for MyoD ( Figure  3a , b), a muscle marker indicating the presence of mesoderm (Hopwood et al., 1989) . These budding protrusions in the anterior region of the embryo also stained positively for the marker XhoxA13, which is normally restricted more posteriorly (Lombardo and Slack, 2001; Christen et al., 2003) with an anterior boundary to somite level 14 in the CNS at late tail bud stages. Mesoderm expression is usually confined to the were fixed with MEMPFA, and whole-mount in situ hybridization assay was performed to detect a muscle marker (MyoD: a, b) and tail markers (Xpo: c, d; XhoxA13: e, f, and XhoxC12: g, h). Note: ectopic expression of markers (arrow) in Tpr-Met-expressing embryos. The animal pole of two-cell stage embryos was injected with 1 pg of Tpr-Met RNA, and animal caps dissected at stage 8.5 were cultured until stage 11.5 or stage 24 to extract total RNA for RT-PCR analysis (i). Xbra (an early mesoderm marker), Zic3 (an early neural marker), muscle actin (a muscle marker), NCAM (a pan-neural marker), Xtwist (a neural crest marker), En2 (a midbrain marker), Krox20 (a hindbrain marker), HoxB9 (a posterior spinal cord marker), and elongation factor-1a (EF-1a, loading control) were detected by PCR. (j) The animal-dorsal blastomere of eight-cell stage embryos was injected with 0.5 pg of Tpr-Met RNA or 250 pg of b-gal RNA as a control. Whole-mount in situ hybridization for Xbra was performed with early gastrula stage embryos (st 10.5).
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A Ishimura et al posterior wall of the tail bud (Figure 3e , f). Expression of XhoxC12, normally found in the posterior region of the neural tube (somite 11 anterior boundary) and throughout the tail tip (Lombardo and Slack, 2001) , was also expressed in the Tpr-Met-induced structures (Figure 3g, h) . Thus, the Tpr-Met-induced protrusions display posterior tail-like molecular characteristics. Since the protrusions induced by Tpr-Met express posterior markers, we determined whether Tpr-Met was able to change the cell fate in ectodermal explants where the influence of adjacent tissues and cell movement on cell fate are minimal. Tpr-Met mRNA (1 pg/embryo) was injected into the animal pole of two-cell stage embryos. Ectodermal animal caps were excised at stage 8.5 and cultured until stage 11.5 or 24. RT-polymerase chain reaction (PCR) analysis of stage 11.5 explants revealed that Xbrachyury (Xbra), an early mesoderm marker (Smith et al., 1991) , and Zic3, a pro-neural and neural crest marker (Nakata et al., 1997) , were induced by Tpr-Met expression at a level that induces ectopic tail-like structures in embryos. While a robust induction of a late mesoderm marker (muscle actin) was observed, only a small induction of a pan neural marker (NCAM) (Gurdon et al., 1984; Jacobson and Rutishauser, 1986; Kim et al., 1997) was evident ( Figure 3i ). Also of interest, a posterior neural marker (Krox20) was induced by Tpr-Met, while an anterior neural marker (En2) was not. Moreover, a very marked induction of the posterior spinal chord marker (HoxB9) and a neural crest marker (Xtwist) was observed, suggesting that Tpr-Met induced a posterior neural cell fate in ectodermal tissue normally destined for an epidermal fate. Confirming that early mesoderm induction was altered, the injection of TprMet mRNA (0.5 pg/embryo) into one animal-dorsal blastomere of eight-cell stage embryos expands Xbra expression in mid-gastrula stage (st 10.5) embryos (Figure 3j ). However, no clear difference was observed for Xnr3 (dorsal early mesoderm) or Xvent1 (ventral early mesoderm; data not shown).
Kinase activity and twin tyrosines 482 and 489 are required for the Tpr-Met-induced phenotype We used Tpr-Met mutants to explore motifs and domains required in a positive fashion for Tpr-Met signaling by engineering additional mutations into the Tpr-Met oncoprotein (Figure 4 ). Consistent with both Tpr-Met oncoprotein signaling and biological activity being dependent on its kinase activity and the two phosphotyrosine residues outside of its catalytic domain (Tyrosines 482 and 489) (Ponzetto et al., 1996; Weidner et al., 1996; Fixman et al., 1997; Jeffers et al., 1998; Maroun et al., 1999; Saucier et al., 2002; Lock et al., 2003) , expression of either the kinase-dead mutant or the Y482F/Y489F mutant are unable to efficiently promote the formation of ectopic structures (13% of embryos; Figure 4d , g, h). In contrast, the absence of tyrosine 482, which is important for the Grb2-independent recruitment of Gab1 (Weidner et al., 1996) (Figure 4a ). These results suggest that the ability to directly bind Gab1 is not a major contributor to the Tpr-Met-induced phenotype, and that direct Grb2 binding is contributory, but not essential for this in vivo event.
Recruitment of either Grb2 or Shc, but not PI-3K to Tpr-Met is sufficient for induction of ectopic structures To better understand the individual contributions of signaling proteins recruited to the Met receptor in a variety of biological events, Tpr-Met variants were generated that are capable of directly recruiting one signaling protein, and thus singly activates a specific downstream signal transduction pathway (Saucier et al., 2002) . These mutants exploit the fact that the recruitment of effectors to the Tpr-Met oncoprotein depends on two tyrosine residues (Y482 and Y489) in its C-terminus (Ponzetto et al., 1996; Weidner et al., 1996; Fixman et al., 1997; Jeffers et al., 1998; Maroun et al., 1999; Saucier et al., 2002; Lock et al., 2003) . These TprMet variants were generated from a mutant of Tpr-Met where tyrosines 482 and 489 were substituted with a phenylalanine residue (Y482F/Y489F), in which the surrounding amino acids (486-494) were substituted with amino acids derived from other receptor tyrosine kinases that correspond to binding motifs for specific signaling proteins (Saucier et al., 2002) . For example, the p85 subunit of PI-3K and PLCg variants contain the respective binding motifs of the PDGF receptor. The Shc1 variant contains the binding motif of the TrkA receptor (Saucier et al., 2002) , and as a negative control, Tpr-MetShc (Y/F) harbors the substitution of a phenylalanine residue in place of a critical tyrosine. The Grb2 variant possesses the binding motif derived from the EGFR, where the Tpr-MetGrb2 (Y/F) negative control also has a phenylalanine residue in place of the inserted tyrosine (Saucier et al., 2002) .
To evaluate the contribution of these receptorassociated signaling proteins to the induction of the ectopic tail-like structures, these Tpr-Met variants were expressed in developing embryos. One animal-dorsal blastomere of eight-cell stage embryos was injected with either b-gal RNA (250 pg) alone, or with Tpr-Met variant RNAs (0.5 pg) and cultured to stage 39. The Grb2 docking mutant was able to induce ectopic structures in the majority of embryos (65%), while the Grb2 (Y/F) mutant failed to promote any phenotypic effects (Figure 5f , h, j). The Shc docking mutant was capable of inducing protrusions (56%), and as expected, the Shc (Y/F) mutant did not induce any phenotypic effect (Figure 5g, i, j) . The PI-3K docking mutant also failed to induce ectopic protrusions (3%), while the PLCg docking mutant displayed a weak ability to induce this event (27%; Figure 5d , e, j). Moreover, the ectopic protrusions that were induced by the PLCg docking mutant were much smaller, less elaborate, and failed to elongate into a tail-like structure (Figure 5e ). Wholemount in situ hybridizations indicated strong Xpo expression in the tips of the tail-like projections induced by Tpr-Met and the Shc, Grb2, and even the PLCgdocking variants (Figure 5k ), confirming their posterior character. While Tpr-Met-injected embryos showed moderate shh expression, the docking variants displayed relatively weak early notochord marker (shh and Xnot) expression along the length of the ectopic structures (data not shown). Using extracts prepared from embryos injected with 1 ng of these mutant RNAs, we confirmed that all mutants were expressed at a comparable level when injected with the same amount of RNA (Figure 5a ). These results indicate that the ability to bind Grb2 or Shc is sufficient in isolation for Tpr-Met to induce these supernumerary structures, while PLCg has a more limited capacity and appears to initiate, but not fully extend these tail-like projections. Finally, the ability to specifically recruit only PI-3K to the TprMet molecule is not sufficient to induce this morphogenetic event.
Direct binding of Shc or Grb2 to Tpr-Met is not required, but in the absence of one, the other is required In addition to a direct interaction with phosphotyrosine 489, Grb2 is also recruited to oncogenic Met indirectly via the recruitment of the adaptor protein Shc. Upon its recruitment to the Met receptor, Shc is phosphorylated on tyrosine residues, which provide binding sites for the SH2 domain of Grb2 (Fixman et al., 1996; Ponzetto et al., 1996; Saucier et al., 2002) . We have shown that a Tpr-Met mutant, unable to bind directly to Grb2 (N491H), retained the ability to efficiently promote the formation of these structures ( Figure 5 ). The substitution of His for Gln in the Tpr-MetN491H mutant specifically disrupts the Tpr-Met and Grb2 association, but not the recruitment of Shc (Fixman et al., 1996; Ponzetto et al., 1996) . Since we have established that the recruitment of Grb2 or Shc is sufficient to induce the formation of ectopic structures with tail-like characteristics, we next tested whether the capacity to recruit Grb2 indirectly through Shc might underlie the ability of the Tpr-MetN491H mutant to induce a morphogenetic event.
The PTB domain of Shc has been identified as the region that directly binds Tpr-Met (Saucier et al., 2002) . We confirmed this result by co-expressing the Shc PTB domain along with either wild-type Tpr-Met, the TprMetShc docking mutant, or the Tpr-MetN491H mutant incapable of directly binding Grb2 (Figure 6a ). Immunoprecipitation (IP) and Western blot analysis demonstrates that all the appropriate proteins were expressed and that the Shc PTB domain was present in the immune complexes when co-expressed with the TprMet variants (Figure 6a ). To determine whether the direct binding of Shc is required for Tpr-Met-induced ectopic structures in the presence or absence of direct Grb2 binding, the Shc PTB domain was used as an inhibitor of direct Shc binding to Tpr-Met. Co-expression of the Shc PTB domain with Tpr-Met failed to inhibit the induction of ectopic structures (Figure 6c , d, i). As expected, expression of the Shc PTB effectively blocked the Tpr-MetShc docking mutant from inducing this morphogenetic event (Figure 6e , f, i). This result demonstrates the ability of the Shc PTB domain to serve as an inhibitor of Tpr-Met/Shc interaction, and further confirms the specificity of the Tpr-MetShc docking variant for the direct recruitment of only Shc (Saucier et al., 2002) . Moreover, the presence of the Shc PTB domain effectively inhibited the formation of ectopic tail-like structures in response to TprMetN491H expression (Figure 6g-i) . These data indicate that in the absence of direct Grb2 binding, the induction of ectopic structures by Tpr-Met becomes Shc-dependent. Direct Grb2 binding is not required, but Grb2 function is necessary for induction of ectopic structures Although, direct binding of Shc or Grb2 to Tpr-Met is not required for the induction of ectopic structures, we have established that in the absence of direct Grb2 binding, a direct interaction between Tpr-Met and Shc is required. Since Grb2 is required for the morphogenesis associated with gastrulation in vertebrates (Cheng et al., 1998; Gupta and Mayer, 1998; Dupont and Blancq, 1999) , we tested whether Grb2 function (either direct or indirect) is critical to the morphogenesis of the ectopic protrusions. Co-expression of dominant-negative Grb2 (DnGrb2) along with Tpr-Met blocked the formation of ectopic structures, and resulted in a phenotypically normal embryo (Figure 7b, c, f) . Expression of DnGrb2 in the neurectoderm was titered to a level that displayed Figure 5 Recruitment of either Grb2 or Shc to Tpr-Met is sufficient for induction of ectopic structures. Two-cell stage embryos were injected with RNA (1 ng) encoding wild-type or point mutants of Tpr-Met, and harvested in lysis buffer after 2 h. Western blot analysis was performed and proteins detected with anti-Met-specific antibody (a). The animal-dorsal blastomere of eight-cell stage embryos was injected with 250 pg b-gal RNA alone (b), or with 0.5 pg of Tpr-Met RNA (c), or mutants that specifically bind: the p85 subunit of PI-3K (Tpr-Metp85 dock) (d), or PLCg (Tpr-MetPLCg dock) (e), or Grb2 (Tpr-MetGrb2 dock) (f), or Shc (Tpr-MetShc dock) (g), or binding mutant controls of Grb2 (Tpr-MetGrb2Y/F) (h), or Shc (Tpr-MetShcY/F) (i). Each phenotype was observed at stage 39. Note: ectopic structures are observed (arrows) in (c, e, f, g). The number of embryos displaying ectopic structures versus the number of embryos injected with RNA(s) as indicated is shown as a percentage in histograms (j). b-Gal, Tpr-Met, and the indicated docking mutant-expressing stage 39 embryos (k) were fixed with MEMPFA, and whole-mount in situ hybridization assay was performed to detect the tail marker (Xpo).
Tpr-Met induces ectopic structures A Ishimura et al no obvious disruption of gastrulation. As expected, the control embryos expressing only the Tpr-MetGrb2 docking mutant displayed ectopic protrusions, and those co-expressing DnGrb2 appeared normal (Figure  7d-f) . These results indicate that Grb2 function is required to mediate Tpr-Met induction of ectopic structures, even though direct Grb2 binding is not essential for this morphogenetic event.
PI-3K, PLCg, and the Ras/Raf/MAPK pathway are required for ectopic structures induced by oncogenic Met The p85 docking mutant of Tpr-Met failed to induce ectopic structures when expressed in neurectoderm of embryos, suggesting that direct recruitment of PI-3K is not sufficient to promote this Tpr-Met-induced phenotype ( Figure 5 ). However, it was still unclear whether PI-3K activity was necessary for Tpr-Met to promote the formation of ectopic structures. We examined the requirement for PI-3K activity by expressing a dominant-negative p85 subunit of PI-3K (DnPI-3K) along with Tpr-Met in the neurectoderm. The DnPI-3K was expressed at a level that completely blocked the formation of ectopic structures, while showing only minor phenotypic effects in the head region (Figure 8e , f, k). An AKT kinase assay was performed on lysates prepared from oocytes expressing Tpr-Met and DnPI-3K. 
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This assay confirmed that the expression of DnPI-3K resulted in a marked decrease in the detection of phosphorylated GSK-3, a downstream target of the pathway (Figure 8a ). Collectively, these data indicate that PI-3K activity, while not sufficient, is required for the morphogenetic event induced by Tpr-Met. As expression of the Tpr-MetPLCg docking mutant was able to initiate ectopic structures in a small percentage of embryos (Figure 5e, j) , we decided to determine whether PLCg is also required to mediate Tpr-Met signaling that results in this morphogenetic event. RNA encoding a dominant-negative form of PLCg (DnPLCg) consisting of the SH2-SH2-SH3 domains of PLCg (Homma and Takenawa, 1992) was injected along with Tpr-Met RNA into one animaldorsal blastomere at the eight-cell stage. Expression of DnPLCg abolished the formation of ectopic structures by Tpr-Met (Figure 8g, k) . Confirmation that the DnPLCg was functional came from IP and Western blot analysis showing that DnPLCg inhibited tyrosine phosphorylation (an indicator of activation) of endogenous PLCg in response to Tpr-Met (Figure 8b ). These data indicate that PLCg is essential for mediating TprMet signaling that results in the morphogenetic effect.
An activated FGF receptor 1, like several FGF signaling pathway elements (Pownall et al., 1996; Tada et al., 1997; Weinstein et al., 1998; Brewster et al., 2000; Hama et al., 2001; Park et al., 2004) , induces ectopic structures. Several members of the Met signaling pathway are also common to the FGF signaling pathway (Furge et al., 2000; Powers et al., 2000) , including Ras/Raf/Mek/MAPK. This suggested the possibility that Raf/Mek/MAPK activity might be a prerequisite for induction of ectopic structures by Tpr-Met. To determine whether Mek/MAPK activity contributed to the Tpr-Met-induced morphogenetic event, we employed dominant-negative kinase suppressor of Ras (DnKSR) (Cacace et al., 1999) , which has been shown to block MAPK activation by preventing the appropriate localization of Mek, an activator of MAPK (Stewart et al., 1999) .
To more clearly define the requirements for Ras/Raf/ Mek in the Tpr-Met-induced phenotype, we also employed a dominant-negative Raf1 (DnRaf, c-Raf1-S621A) (Fabian et al., 1993) , and a dominant-negative Ras (DnRas, H-RasN17) (Whitman and Melton, 1992) . Tpr-Met was expressed alone or with either DnRas, DnRaf, or DnKSR in neurectoderm of developing embryos. Inhibition of Ras, Raf, or Mek blocked the induction of ectopic structures in response to Tpr-Met signaling, and the vast majority of embryos appeared phenotypically normal (Figure 8e , h-k). As expected, the dominant-negative forms of all three MAPK pathway members prevented Tpr-Met induction of MAPK phosphorylation, confirming their efficacy (Figure 8c) . Thus, the Ras/Raf/MAPK pathway plays a critical role in mediating Tpr-Met-induced morphogenetic events.
Although it is unclear whether Tpr-Met activates the Ras/Raf/Mek pathway via direct binding to Shc and/or Grb2 (Furge et al., 2000) , the Tpr-Met docking mutants that specifically bind Shc or Grb2 can induce this pathway and promote the formation of ectopic Tpr-Met induces ectopic structures A Ishimura et al structures in embryos. Since, we have established that the Ras/Raf/Mek pathway is essential for the induction of ectopic structures, it was of interest to test whether activation of this pathway is sufficient for this morphogenetic event. To this end, we injected one-cell stage embryos with RNA encoding Tpr-Met, activated Ras, activated Raf, or activated Mek at various concentrations. Lysates were prepared at stage 6.5 and immunoblotted with anti-phospho-MAPK antibodies to determine the amount of each RNA product that would yield a similar level of phosphorylated MAPK, an indicator of MAPK activity (Figure 9a ). Once this concentration was determined, all RNAs were diluted to correspond to the optimal amount of Tpr-Met RNA injected for the induction of ectopic structures (approximately a 20-fold dilution), or a four-to fivefold increase in these concentrations. Tpr-Met, activated Ras, activated Raf, or activated Mek were expressed in neurectoderm at concentrations that result in Mek phosphorylation at levels that are either equivalent to Tpr-Met or increased by four-to fivefold. Injection of activated Ras at 1 pg did not induce ectopic structures (0%), but injection of 4 pg of RNA induced this phenotype in 40% of embryos (Figure 9d, e, j) . Introduction of activated Raf RNA at 60 pg, which is estimated to result in equivalent MAPK phosphorylation as Tpr-Met, weakly induced ectopic structures (8%). In contrast, a fivefold increase in activated Raf expression (300 pg RNA/embryo) caused 45% of embryos to display ectopic structures (Figure 9f, g, j) , similar to results observed for activated Ras (Figure 9j) . Surprisingly, activated Mek expression, even at concentrations that induced high levels of MAPK phosphorylation, failed to induce any ectopic structures (Figure 9i ). Collectively, these data indicate that activated Ras and Raf can induce ectopic structures when expressed at levels that induce four-to five-fold more MAPK activation when compared to Tpr-Met. However, activation of MAPK alone is not sufficient for the induction of ectopic structures. Thus, MAPK activation is necessary, but not sufficient for promotion of ectopic structures. 
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Discussion
Many substrates have been identified that associate with activated receptor tyrosine kinases; however, it is unclear which signaling pathways mediate transformation by the oncogenic variants of these receptors. While HGF/SF-Met signaling is normally involved in many aspects of embryogenesis, aberrant signaling has been implicated in both tumor development and progression (Jeffers et al., 1996) . In particular, HGF/SF-Met signaling was shown to play a significant role in promoting tumor cell invasion and metastasis (Rong and Vande Woude, 1994) . This process has striking similarities to morphogenetic events controlled by Met, such as tubulogenesis and cell scattering. These events, gastrulation movements, and many of the subsequent tissue remodeling, all involve the epithelial-mesenchymal transition (EMT). EMT is an orderly process where cell-cell contacts and cell-substrate contacts are altered, releasing epithelial cells from the surrounding tissue along with a dramatic remodeling of the cytoskeleton (Thiery, 2002; Kang and Massague, 2004; Radisky, 2005) . De-regulation of EMT is also recognized as an important event in the progression and metastasis of cancer (Thiery, 2002; Kang and Massague, 2004; Radisky, 2005) . We hope to gain insight into the general mechanism of cellular transformation by identifying intracellular signaling pathways utilized by the Tpr-Met oncoprotein that promote morphogenetic outgrowths.
In this study, we have exploited the Xenopus embryonic system to define the contribution of various proximal-binding partners and downstream signaling pathways of the Met receptor in morphogenetic events. As depicted in Figure 1 , we show that the oncogenic Met protein induces ectopic structures when expressed in the dorsal region of the embryo, and that this effect is not dependent upon cytoplasmic localization, since a myristylated form induces the same phenotype (Figure 2c ). This morphogenetic phenotype is dependent upon Tpr-Met kinase activity, and requires the presence of the twin phosphotyrosine (Y482 and Y489) residues located outside the catalytic domain of the receptor (Figure 4) . Using variant forms of Tpr-Met that are engineered to recruit a specific signaling protein of choice (Saucier et al., 2002) , we demonstrate that the sole recruitment of either the Grb2 or the Shc adaptor protein is sufficient to induce ectopic structures and anterior reduction, but the recruitment of PI-3K alone is insufficient for this effect ( Figure 5 ). In contrast, the specific recruitment of PLCg initiates the induction of ectopic protrusions, but fails to maintain or elongate these supernumerary structures. Nevertheless, the direct recruitment of the Grb2 or the Shc adaptor protein is dispensable for the induction of ectopic morphogenetic structures, except when both signaling adaptors are prevented from directly associating with oncogenic Met (Figure 6 ). This suggests that in the absence of direct association of either adaptor alone, the morphogenetic induction process becomes dependent upon the other molecule, which maintains access to oncogenic Met. Moreover, we show that Tpr-Met-dependent induction of ectopic structures requires Grb2 function regardless of whether Grb2 can be directly recruited to Tpr-Met (Figure 7) . A DnGrb2 can block Tpr-Met-induced ectopic structures, suggesting that it performs a required function downstream in the oncogenic Met signaling pathway. Consistent with this concept, it has been shown that treatment of MDCK epithelial cells with Figure 9 Although Ras and Raf signaling can induce ectopic structures, activation of the MAPK pathway alone is not sufficient for this event. The indicated RNAs and concentrations were injected into one-cell stage embryos, cultured until stage 6.5, and Western blot analysis performed with anti-phospho-MAPK antibody (a; upper panel) or anti-Erk2 antibody (a; lower panel). The animal-dorsal blastomere of eight-cell stage embryos was injected with 250 pg b-gal RNA alone (b), or with 0.5 pg of Tpr-Met RNA (c), or activated Ras RNA (1 pg in d; 4 pg in e) or activated Raf RNA (60 pg in f; 300 pg in g), or activated Mek RNA (7.5 pg in h; 37.5 pg in i). Each phenotype was observed at stage 39. Note: ectopic structures are observed (arrows) in (c, e, g). The number of embryos displaying ectopic structures versus the number of embryos injected with RNA(s) as indicated is shown as a percentage in histograms (j). These data are representative of three independent experiments.
Tpr-Met induces ectopic structures A Ishimura et al antagonists of the Grb2 SH2 domain potently blocks HGF-induced cell motility, matrix invasion, and branching morphogenesis, but does not inhibit the mitogenic response (Atabey et al., 2001) . Although activation of PI-3K or PLCg alone are not sufficient for induction and maintenance of Tpr-Met-induced ectopic structures, both signaling molecules are necessary for this morphogenetic event (Figure 8) .
Anterior truncations and posterior duplications similar to those reported here have been observed with the misexpression of several FGF signaling pathway components, including eFGF, Xbra, Laloo, Gli2, XER81, and SNT1 (Pownall et al., 1996; Tada et al., 1997; Weinstein et al., 1998; Chen et al., 1999; Brewster et al., 2000; Hama et al., 2001) . In Xenopus embryos, it has also recently been shown that overexpression of the EphA4 receptor induced ectopic structures, but the mechanism was dependent upon activation of the FGF signaling pathway as well (Park et al., 2004) .
In vertebrates, FGF receptor-mediated signal transduction plays a critical role during mesoderm formation, and is required for the correct formation of the trunk and tail in Xenopus embryos. However, analysis of chimeric mouse embryos harboring an inactive truncated FGFR displayed a primary defect in the ability of ectodermal precursor cells to undergo EMT and traverse the primitive streak (Ciruna et al., 1997) . At least a portion of mesodermal cells express Twist, a transcription factor, known to be essential for proper gastrulation, mesoderm formation, and neural crest migration. Twist plays a role in EMT during development and it can also mediate EMTs during tumor progression (Vernon and LaBonne, 2004; Yang et al., 2004) . HGF/ SF induces behavior resembling some aspects of the intrinsic EMT in the chick embryo (Stern et al., 1990; Shook and Keller, 2003) , and local application of HGF to chick embryos induced the formation of axial structures similar to primitive streak and/or neural plate (Stern et al., 1990) . In our system, ectopic expression of Tpr-Met in embryos induces supernumerary structures, but it is unclear whether these structures form by transforming ectoderm to neural and mesoderm lineages, followed by proliferation and extension of these structures. In support of this possibility, Tpr-Met expression causes a robust expansion of Xbra (early mesoderm marker) expression during gastrulation (Figure 3j) , and the induction of Zic3 (neural crest marker) in gastrula stage ectodermal explants (Figure 3i ). Alternatively, Tpr-Met expression may drive the migration of neurectoderm progenitors to a localized area where they are capable of inducing a morphogenetic structure from which some mesoderm and posterior neural derivatives form.
Constitutively active members of the FGFR pathway such as Ras, Raf, and MAPK induce mesoderm formation, while dominant-negative versions of these proteins inhibit this process (Whitman and Melton, 1992; MacNicol et al., 1993; LaBonne and Whitman, 1994; LaBonne et al., 1995; Umbhauer et al., 1995) . Mesoderm induction downstream of the FGF receptor requires the stimulation of the Ras/MAPK cascade (reviewed by Harland and Gerhart, 1997; Yasuo and Lemaire, 2001) . Tpr-Met also strongly activates the MAPK cascade in the Xenopus (Fabian et al., 1993; Mood et al., 2005) and mammalian systems (reviewed by Furge et al., 2000) . We showed that expression of dominant-negative forms of Ras, Raf, or KSR effectively prevents MAPK activation (Figure 8c) , and precludes the induction of ectopic structures in response to oncogenic Met (Figure 8d-k) . Thus, MAPK activation is necessary for the induction of ectopic tail-like structures.
Although MAPK activity is required for the Tpr-Metinduced phenotype, we tested whether activation of MAPK is sufficient for these effects. Activation of MAPK by activated Ras or Raf was capable of inducing ectopic structures, but only at levels four-to fivefold above that required by Tpr-Met (Figure 9 ). Moreover, activated Mek alone failed to induce ectopic structures even at these high levels ( Figure 9i ). Collectively, these data indicate that activation of MAPK is necessary, but not sufficient to induce supernumerary structures.
These results emphasize the importance of studying signaling molecules in the regulatory context that is provided by receptor/effector interactions. The demonstration that the Met receptor is frequently deregulated in human tumors highlights the need to fully understand the signaling network of this receptor implicated in controlling cell movement and growth, which are critical to morphogenetic events. Furthermore, it is interesting to note that the transcription factor Twist, a critical regulator of embryonic morphogenesis, is strongly induced by oncogenic Met in ectodermal explants (Figure 3i ). Twist has also been identified as a key player in mammary gland metastasis (Yang et al., 2004) and offers some of the most direct evidence that EMT may be essential for this process. Consistent with this concept, Met has been linked to the EMT in NBT-II epithelial bladder carcinoma cells, where HGF expression caused increased invasiveness in 3D collagen gels and a tumorigenic advantage in nude mice (Bellusci et al., 1994) . Therefore, therapeutic strategies to block oncogenic Met function leading to the induction or maintenance of EMT should be investigated.
The inhibition of c-Met through an array of receptor antagonists has been shown to inhibit the motility, invasiveness, and tumorigenicity of human tumor cell lines. A number of approaches have been devised to block Met receptor function, including: (1) c-Met biological inhibitors (dominant-negative receptors and peptides) and neutralizing antibodies; (2) HGF antagonists and neutralizing antibodies; (3) small molecule inhibitors (reviewed in Christensen et al., 2005) . Derivation of small molecule inhibitors with selectivity towards the Met receptor is an area of intense focus. One molecule, SU11274, is an effective inhibitor of c-Met signaling functions in NIH 3T3 cells expressing activated Met mutants H1112Y, M1268T, and Tpr-Met, but not L1213V or Y1248H (Sattler et al., 2003; Berthou et al., 2004) . Another selective inhibitor, PHA-665752, is a potent ATP-competitive inhibitor that blocks Met receptor signaling in tumor cell lines and gastric Tpr-Met induces ectopic structurescarcinoma xenograft models (Christensen et al., 2003) . Identifying the tumor types and genetic backgrounds for further clinical evaluation of Met inhibitors will be crucial, but the evidence supports the Met receptor as a significant and feasible target for therapeutic intervention. The present studies use the Xenopus embryonic system to define and examine the oncogenic Met signaling network, and may serve to design and test novel therapeutic strategies for intervention in cancers displaying deregulation of the Met receptor.
Materials and methods
Generation of substrate specific variants of Tpr -Met
The cloning and characterization of the Tpr-Met, Y482F, Y482/489F, SMS-Met, and signaling-specific variant cDNAs have been previously described (Fixman et al., 1996; Kamikura et al., 1996 Kamikura et al., , 2000 Saucier et al., 2002) . These mutant cDNAs were subsequently subcloned into the EcoRI site of the pCS2 þ vector, except in the case of SMS-Met which was inserted into the StuI site of pCS2 þ . The PCR was used to introduce a mutation in Xenopus Grb2 (accession # AJ223061) that disrupts the SH2-binding site by creating a Lysine substitution for Arginine at amino-acid position 86, and then inserted into pCS2 þ . The DnPLCg (accession # BC070837) consisting of the SH2-SH2-SH3 domains was created by PCR, and inserted into pCS2 þ . The Shc1 PTB domain was created by PCR using the Xenopus Shc sequence (accession # BC089178.1). All PCRs were performed using a Xenopus oocyte library (gift of Alan Wolfe) as template.
Preparation of Xenopus embryos, synthetic RNA, lineage trace, and animal cap explants Embryos were obtained by in vitro fertilization after induction of females with 500 U of human chorionic gonadotropin (Sigma, St Louis, MO). pCS2 þ plasmids containing Tpr-Met constructs, b-gal, were linearized and capped mRNA was made using the SP6 mMessage mMachine kit (Ambion, Austin, Texas). Experiments employing DnKSR (Cacace et al., 1999) RNA, DnPI3K (Carballada et al., 2001 ) RNA, DnPLCg (Chen et al., 1996b) RNA were performed by injecting into one animal-dorsal blastomere of eight-cell stage embryos with indicated amounts of RNAs. Lineage tracing was performed by b-gal staining as previously described (Sive et al., 2000) . Briefly, Xenopus embryos injected with 250 pg of b-gal mRNA at the eight-cell stage were cultured until stage 39, then rinsed with 0.7 Â phosphate-buffered saline (PBS), and fixed for 1 h on ice in freshly prepared fixation solution (0.7 Â PBS containing 2% formaldehyde, 0.2% glutaraldehyde, 0.02% Triton X-100 and 0.01% sodium deoxycholate). Embryos were rinsed twice with 0.7 Â PBS and stained at 301C in 0.7 Â PBS containing 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mg/ml X-gal, 1 mM MgCl 2 . Embryos were fixed in MEM-PFA (0.1 M MOPS (pH 7.4), 2 mM EGTA, 1 mM MgSO 4 , and 4% paraformaldehyde) for 1 h and photographed with a Nikon CCD camera. Animal cap explants were made using forceps or the Gastromaster (Xenotek Engineering) at stage 8.5. The explants were cultured as described previously (Maeda et al., 2001 ).
Whole-mount in situ hybridization Plasmids containing cDNAs were obtained, linearized, and digoxygenin-labeled riboprobes were synthesized using MegaScript kit (Ambion) as specified: Xpo (T Sargent, PstI, T7 polymerase), Xhox-C12, Xhox-A13 (J Slack, NotI, T3 polymerase), MyoD (J Gurdon, BamHI, Sp6 polymerase), Xbra (S Moody, BglII, T7 polymerase), Xnr3 (S Moody, EcoRI, T7 polymerase), Xvent1 (C Niehrs, SalI, T7 polymerase), shh (I Dawid, EcoRI, T7 polymerase), and Xnot1 (I Dawid, HindIII, T7 polymerase). Whole-mount in situ hybridization was essentially carried out as described by Harland with modification (Maeda et al., 2001) . For detection, BM Purple (Roche, Indianapolis, IN) was used as a chromogenic substrate. The reaction was stopped and the embryos were refixed in MEMPFA for 1 h. When pigmented embryos were used, embryos were bleached with a solution containing 1% H 2 O 2 , 5% Formamide, and 0.5 Â SSC after staining (Mayor et al., 1995) .
RT-PCR assay
Total RNA from animal cap explants and staged embryos was extracted using Trizol (Gibco BRL, Gaithersburg, MD). Complementary DNA was synthesized from 1 mg total RNA using SuperScriptII (Gibco BRL). Polymerase chain reaction was performed in 50 ml containing 1 mg of cDNA, 1 Â Taq buffer, 1.5 mM MgCl 2 , 0.2 mM each of dNTPs, 350 ng of each primer, and 1 U of AmpliTaq DNA polymerase (Perkin Elmer, Wellesley, MA). The primer sequences and conditions for NCAM, Krox20, HoxB9, muscle actin, and EF-1a have been previously published (Hemmati-Brivanlou and Melton, 1994) . Xtwist, Xbra, Zic3, and En2 primer sequences were posted at the Xenbase web page www.xenbase.org/genomics/ genomics.html.
Immunoprecipitation and Western blot analysis
Embryos were prepared with ice-cold lysis buffer (20 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40 containing 1:50 diluted Protease Inhibitor Cocktail Set III, Calbiochem, La Jolla, CA), as previously described (Chong et al., 2000) , followed by extraction with 1.1.2-Trichlorotrifluoroethane (Sigma) at a 1:1 (vol/vol) ratio. Immunoprecipitations were conducted on 10 embryo equivalents with polyclonal rabbit antibody raised against either PLCg (UBI, Charlottesville, VA) or Tpr-Met (Santa Cruz, Santa Cruz, CA) for 4 h or overnight and protein-A/G agarose (Santa Cruz) for an additional 1 h. Following three washes with lysis buffer, precipitants were separated by SDS-PAGE. The proteins were transferred to a membrane (Immobilon-P, Millipore, Billerica, MA), blocked with 5% non-fat dry milk in TBS containing 0.1% Tween-20 (TBST), and incubated with the indicated antibodies. For antiphosphotyrosine blotting, 5% BSA in TBST was used as a blocking reagent. AKT assays were performed using the AKT assay kit (Cell Signaling, Beverly, MA). Briefly, embryo lysates were prepared as above, AKT was immunoprecipitated with the supplied immobilized AKT antibody, immunocomplexes were incubated in kinase buffer (25 mM Tris (pH 7.5), 5 mM b-glycerophosphate, 2 mM DTT, 0.1 mM sodium vanadate, 1 mg/ml leupeptin, 200 mM ATP) with 1 mg of a GSK-3 fusion protein. Samples were resolved by 12% SDS-PAGE, immunoblotted and phosphorylated GSK-3 substrate was detected using a phospho-GSK-3a/b (Ser21/9) antibody (Cell Signaling). Direct Western analysis of lysates were performed as previously described (Park et al, 2004 ) with antibodies to phosphorylated MAPK (monoclonal; Sigma), ERK2 (polyclonal; UBI), Shc (monoclonal; BD Transduction Laboratories, Lexington, KY), phosphotyrosine (monoclonal; UBI), Met (polyclonal; Santa Cruz), Myc (monoclonal; Roche). Proteins were visualized using an appropriate secondary antibody coupled to HRP (UBI), followed by application of enhanced chemiluminescence reagents (Amersham, Piscataway, NJ).
